FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmaceutics and the use of the CFTR (cystic fibrosis transmembrane conductivity regulator) corrector for the prevention and/or treatment of decreased or disturbed cerebral perfusion, where the CFTR corrector is a cyclopropane carboxamide derivative selected from the group consisting of lumacaftor, tezacaftor, C18 and their pharmaceutically acceptable salts and solvates.
EFFECT: use of the invention enables to effectively prevent and/or treat decreased or disturbed cerebral perfusion.
3 cl, 19 dwg, 1 ex
Authors
Dates
2024-06-03—Published
2019-09-09—Filed